The executive director of Moderna acknowledged GenIbet Biopharmaceuticals, a spin-off company from iBET, for the role played in 2015 that boosted the development of mRNA-based vaccines.
“Moderna is very thankful to GenIbet Biopharmaceuticals. They partnered together to take the very first Moderna mRNA vaccine in the clinic at the end of 2015. The GenIbet team provided Moderna with a high quality GMP product and we are thankful for its work” Stéphane Bancel, CEO, MODERNA
Paula Alves, CEO of iBET, and Raquel Fortunato, CEO of GenIbet commented on the collaborative research work that enabled the production of different mRNA-based products for clinical trials.
@ Expresso Online
“Moderna agradece a Portugal ter ajudado no desenvolvimento da vacina para a covid-19” – Full article available here (only in Portuguese)
@ RTP 1 (only in Portuguese)
@ SIC Notícias (only in Portuguese)
@ TVI (only in Portuguese)